These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11358172)

  • 1. Comparison of the activity spectra against pathogens of bacterial strains producing a mutacin or a lantibiotic.
    Morency H; Mota-Meira M; LaPointe G; Lacroix C; Lavoie MC
    Can J Microbiol; 2001 Apr; 47(4):322-31. PubMed ID: 11358172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro inhibition activity of nisin A, nisin Z, pediocin PA-1 and antibiotics against common intestinal bacteria.
    Le Blay G; Lacroix C; Zihler A; Fliss I
    Lett Appl Microbiol; 2007 Sep; 45(3):252-7. PubMed ID: 17718835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production, purification, sequencing and activity spectra of mutacins D-123.1 and F-59.1.
    Nicolas GG; LaPointe G; Lavoie MC
    BMC Microbiol; 2011 Apr; 11():69. PubMed ID: 21477375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Antimicrobial Activity Between the Broad Spectrum Bacteriocin Garvicin KS and Nisin, Farnesol and Polymyxin B Against Gram-Positive and Gram-Negative Bacteria.
    Chi H; Holo H
    Curr Microbiol; 2018 Mar; 75(3):272-277. PubMed ID: 29058043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens.
    Mota-Meira M; LaPointe G; Lacroix C; Lavoie MC
    Antimicrob Agents Chemother; 2000 Jan; 44(1):24-9. PubMed ID: 10602718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The group I strain of Streptococcus mutans, UA140, produces both the lantibiotic mutacin I and a nonlantibiotic bacteriocin, mutacin IV.
    Qi F; Chen P; Caufield PW
    Appl Environ Microbiol; 2001 Jan; 67(1):15-21. PubMed ID: 11133423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antimicrobial activity of two new mutacins.
    Nicolas GG; LaPointe G; Lavoie MC
    West Indian Med J; 2010 Dec; 59(6):602-6. PubMed ID: 21702231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics and identification of bacteriocins produced by Lactococcus lactis subsp. lactis 194-K].
    Ustiugova EA; Timofeeva AV; Stoianova LG; Netrusov AI; Katrukha GS
    Prikl Biokhim Mikrobiol; 2012; 48(6):618-25. PubMed ID: 23330388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriocin-Based Synergetic Consortia: a Promising Strategy to Enhance Antimicrobial Activity and Broaden the Spectrum of Inhibition.
    Soltani S; Biron E; Ben Said L; Subirade M; Fliss I
    Microbiol Spectr; 2022 Feb; 10(1):e0040621. PubMed ID: 35170996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual antibacterial mechanisms of nisin Z against Gram-positive and Gram-negative bacteria.
    Kuwano K; Tanaka N; Shimizu T; Nagatoshi K; Nou S; Sonomoto K
    Int J Antimicrob Agents; 2005 Nov; 26(5):396-402. PubMed ID: 16226432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V.
    Field D; Quigley L; O'Connor PM; Rea MC; Daly K; Cotter PD; Hill C; Ross RP
    Microb Biotechnol; 2010 Jul; 3(4):473-86. PubMed ID: 21255345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery.
    Escano J; Ravichandran A; Salamat B; Smith L
    Appl Environ Microbiol; 2017 Jul; 83(14):. PubMed ID: 28500042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of reuterin in combination with nisin against food-borne pathogens.
    Arqués JL; Fernández J; Gaya P; Nuñez M; Rodríguez E; Medina M
    Int J Food Microbiol; 2004 Sep; 95(2):225-9. PubMed ID: 15282134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosynthetic characterization and biochemical features of the third natural nisin variant, nisin Q, produced by Lactococcus lactis 61-14.
    Yoneyama F; Fukao M; Zendo T; Nakayama J; Sonomoto K
    J Appl Microbiol; 2008 Dec; 105(6):1982-90. PubMed ID: 19120645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioengineering of the model lantibiotic nisin.
    Field D; Cotter PD; Ross RP; Hill C
    Bioengineered; 2015; 6(4):187-92. PubMed ID: 25970137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of bacteriocin-like substances by human oral streptococci.
    Fabio U; Bondi M; Manicardi G; Messi P; Neglia R
    Microbiologica; 1987 Oct; 10(4):363-70. PubMed ID: 3695984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Bac' to the future: bioengineering lantibiotics for designer purposes.
    Molloy EM; Ross RP; Hill C
    Biochem Soc Trans; 2012 Dec; 40(6):1492-7. PubMed ID: 23176504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and characterization of NAI-802, a new lantibiotic produced by two different Actinoplanes strains.
    Simone M; Monciardini P; Gaspari E; Donadio S; Maffioli SI
    J Antibiot (Tokyo); 2013 Feb; 66(2):73-8. PubMed ID: 23168402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
    Putnam SD; Castanheira M; Moet GJ; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):393-401. PubMed ID: 20022192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.